Ge Long Hui·2025-12-18 07:27Core Viewpoint - Guohai Securities' report indicates that East China Pharmaceutical's dual-target GLP-1 is progressing smoothly, with a positive outlook on the weight loss market development [1] Group 1: Clinical Trial Results - The company's wholly-owned subsidiary, Zhongmei East China, has developed an innovative long-acting agonist HDM1005, targeting both GLP-1 and GIP receptors, which has shown positive results in Phase II clinical trials for weight management in China [1] - The weight loss effects of HDM1005 were significant, with the 0.5mg, 1.0mg, 2.0mg, and 4.0mg groups showing weight changes of -7.47%, -9.73%, -13.31%, and -13.28% respectively after 22 weeks, compared to a -2.46% change in the placebo group [1] - In addition to weight reduction, HDM1005 also demonstrated significant improvements in other cardiovascular and metabolic indicators, including glucose metabolism, blood pressure, and blood lipids [1] Group 2: Company Positioning - The company is recognized as a leading domestic prescription drug enterprise, with a rich product pipeline and industry-leading channel and brand capabilities [1] - The company is expected to achieve coordinated growth through both internal and external development strategies [1]